Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Growth Officer | November 07, 2023 | November 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date November 07, 2023 · Filed November 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 124,511 |
Reported balance
After 2023-11-07 transaction · row 1
1 source rowRow 1 · 2023-11-07 · Sale · Disposed 382 · Balance 124,511 F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2023 Filed Nov 8, 2023 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 382 | $12.65 | $4,832.30 |
DisclosureSEC source: 0001562180-23-007594 · primarydocument.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,511 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 273 | $21.82 | $5,956.10 |
DisclosureSEC source: 0001562180-23-006680 · primarydocument.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,893 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 367 | $35.28 | $12,947.76 |
DisclosureSEC source: 0001562180-23-005760 · primarydocument.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,166 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 43,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002492 · primarydocument.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,220 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 3,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002492 · primarydocument.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,974 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 16,909 | $76.16 | $1,287,779.29 |
DisclosureSEC source: 0001562180-23-002580 · primarydocument.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,799 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,942 | $76.16 | $224,060.95 |
DisclosureSEC source: 0001562180-23-002580 · primarydocument.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,708 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,570 | $76.16 | $119,570.26 |
DisclosureSEC source: 0001562180-23-002580 · primarydocument.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,650 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 937 | $75.28 | $70,535.39 |
DisclosureSEC source: 0001562180-23-002492 · primarydocument.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,038 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,923 | $76.36 | $146,844.90 |
DisclosureSEC source: 0001645113-23-000030 · wf-form4_167779437669900.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,975 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:00 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 31,691 | $76.97 Strike: $76.97 | $2,439,256.27 |
DisclosureSEC source: 0001645113-23-000030 · wf-form4_167779437669900.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,691 Underlying: Ordinary Shares · 31,691 shares Expires 2033-02-27 F3 · derivative.exercise_date: Options to buy 31,691 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:00 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 19,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000030 · wf-form4_167779437669900.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,898 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 387 | $108.00 | $41,796.00 |
DisclosureSEC source: 0001645113-23-000008 · wf-form4_167330639201251.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,843 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 269 | $79.04 | $21,260.95 |
DisclosureSEC source: 0001645113-22-000075 · wf-form4_166249873695422.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,230 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:45 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 312 | $59.08 | $18,431.40 |
DisclosureSEC source: 0001645113-22-000059 · wf-form4_165723033557650.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,499 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:54 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,669 | $71.19 | $261,196.11 |
DisclosureSEC source: 0001645113-22-000031 · wf-form4_164703562615399.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,187 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. F2 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:56 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,481 | $70.10 | $173,918.10 |
DisclosureSEC source: 0001645113-22-000030 · wf-form4_164686295456528.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,908 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 21:56 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,294 | $69.55 | $368,197.70 |
DisclosureSEC source: 0001645113-22-000030 · wf-form4_164686295456528.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,389 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 23:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,914 | $70.41 | $134,759.00 |
DisclosureSEC source: 0001645113-22-000020 · wf-form4_164669542266568.xml · nonDerivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,683 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 23:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,632 | $73.34 | $193,030.88 |
DisclosureSEC source: 0001645113-22-000020 · wf-form4_164669542266568.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,597 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:23 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 6,231 | $80.59 Strike: $80.59 | $502,156.29 |
DisclosureSEC source: 0001645113-22-000020 · wf-form4_164669542266568.xml · derivative · entry 6 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,231 Underlying: Ordinary Shares · 6,231 shares Expires 2032-02-29 F4 · shares: Options to buy 6,231 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:23 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 38,027 | $80.59 Strike: $80.59 | $3,064,595.93 |
DisclosureSEC source: 0001645113-22-000020 · wf-form4_164669542266568.xml · derivative · entry 5 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,027 Underlying: Ordinary Shares · 38,027 shares Expires 2032-02-29 F3 · shares: Options to buy 38,027 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 997 | $74.50 | $74,274.51 |
DisclosureSEC source: 0001645113-22-000020 · wf-form4_164669542266568.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,229 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:23 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 21,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000020 · wf-form4_164669542266568.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,226 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 21, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 30 | $140.18 | $4,205.40 |
DisclosureSEC source: 0001645113-21-000106 · wf-form4_163104675810103.xml · nonDerivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,512 F4 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 150 | $139.24 | $20,885.70 |
DisclosureSEC source: 0001645113-21-000106 · wf-form4_163104675810103.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,542 F3 · shares: On September 3, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 150 shares in multiple trades at prices ranging from $138.81 to $139.78. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 321 | $138.27 | $44,385.63 |
DisclosureSEC source: 0001645113-21-000106 · wf-form4_163104675810103.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,692 F2 · shares: On September 3, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 321 shares in multiple trades at prices ranging from $137.75 to $138.56. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 156 | $138.23 | $21,564.19 |
DisclosureSEC source: 0001645113-21-000106 · wf-form4_163104675810103.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,013 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 20:41 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,063 | $148.71 | $306,788.73 |
DisclosureSEC source: 0001645113-21-000100 · wf-form4_162828248977664.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,169 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,654 | $149.43 | $247,157.22 |
DisclosureSEC source: 0001645113-21-000097 · wf-form4_162811132288298.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,232 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 31, 2021 Filed Mar 11, 2022 21:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 3,717 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000031 · wf-form4_164703562615399.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,717 Underlying: Ordinary Shares · 3,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| July 31, 2021 Filed Mar 11, 2022 21:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,717 | $154.01 | $572,455.17 |
DisclosureSEC source: 0001645113-22-000031 · wf-form4_164703562615399.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:29 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 154 | $137.12 | $21,116.79 |
DisclosureSEC source: 0001645113-21-000083 · wf-form4_162577972656216.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,886 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 23,540 | $215.00 | $5,061,100.00 |
DisclosureSEC source: 0001645113-21-000080 · wf-form4_162344315214063.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,732 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| May 05, 2021 Filed May 6, 2021 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,290 | $199.67 | $257,574.30 |
DisclosureSEC source: 0001645113-21-000065 · wf-form4_162033218703219.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,272 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| May 04, 2021 Filed May 5, 2021 20:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,043 | $200.86 | $209,492.81 |
DisclosureSEC source: 0001645113-21-000063 · wf-form4_162024533376835.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,562 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 2,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000063 · wf-form4_162024533376835.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,333 | $204.10 | $476,165.30 |
DisclosureSEC source: 0001645113-21-000063 · wf-form4_162024533376835.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 3,524 | $131.09 | $461,961.16 |
DisclosureSEC source: 0001645113-21-000047 · wf-form4_161541063414261.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,272 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 2,627 | $130.81 | $343,627.36 |
DisclosureSEC source: 0001645113-21-000047 · wf-form4_161541063414261.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,796 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 13,987 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-21-000042 · wf-form4_161532462367557.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,987 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,550 | $131.53 | $598,461.50 |
DisclosureSEC source: 0001645113-21-000042 · wf-form4_161532462367557.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,423 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 13,987 | $7.15 | $100,007.05 |
DisclosureSEC source: 0001645113-21-000042 · wf-form4_161532462367557.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 2,658 | $137.55 | $365,618.53 |
DisclosureSEC source: 0001645113-21-000035 · wf-form4_161498420075158.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,986 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 2,174 | $150.78 | $327,795.72 |
DisclosureSEC source: 0001645113-21-000035 · wf-form4_161498420075158.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,644 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:46 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 20,004 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000027 · wf-form4_161489794759755.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,004 Underlying: Ordinary Shares · 20,004 shares Expires 2031-03-01 F3 · derivative.exercise_date: Options to buy 20,004 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:46 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 10,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000027 · wf-form4_161489794759755.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,818 F2 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:46 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 912 | $152.05 | $138,672.34 |
DisclosureSEC source: 0001645113-21-000027 · wf-form4_161489794759755.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,932 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Share Units vested on February 27, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 3,086 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000025 · wf-form4_161471986510098.xml · derivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,086 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,086 | $149.10 | $460,122.60 |
DisclosureSEC source: 0001645113-21-000025 · wf-form4_161471986510098.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.